Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note published on Thursday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners lowered their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 1.3 %

Shares of NASDAQ AWH traded up $0.01 during midday trading on Thursday, hitting $0.87. The stock had a trading volume of 12,096 shares, compared to its average volume of 75,731. The business’s 50 day moving average is $0.87 and its 200-day moving average is $1.52. Aspira Women’s Health has a 52 week low of $0.74 and a 52 week high of $5.65.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same period last year, the company earned ($0.28) earnings per share. On average, equities research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.